After reverse transcription of the viral RNA genome, HIV integrase associates with a series of cellular factors and the proviral DNA. This pre-integration complex migrates to the cell nucleus, where integration into the host cell genome takes place. The diverse activities of HIV integrase create the opportunity for different classes of inhibitors that interact with distinct binding sites in the enzyme, and have non-overlapping resistance profiles.



Tibotec's discovery program is aimed at the discovery of new small molecule integrase inhibitors.